{"id":"pioglitazone-tzd","safety":{"commonSideEffects":[{"rate":"~5-10%","effect":"Weight gain"},{"rate":"~5-10%","effect":"Fluid retention and edema"},{"rate":"variable","effect":"Hypoglycemia (when combined with other agents)"},{"rate":"~5%","effect":"Headache"},{"rate":"~5%","effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL595","moleculeType":"Small molecule","molecularWeight":"356.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a thiazolidinedione, pioglitazone binds to PPAR-γ in adipose tissue and muscle, enhancing insulin signaling and glucose uptake. This reduces hepatic glucose production and improves peripheral insulin sensitivity, leading to lower blood glucose levels without directly stimulating insulin secretion.","oneSentence":"Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:21.210Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05305287","phase":"PHASE4","title":"Quantifying Hepatic Mitochondrial Fluxes in Humans","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2022-11-01","conditions":"Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders","enrollment":60},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT05040087","phase":"NA","title":"Changing the Natural History of Type 2 Diabetes (\"CHANGE\" Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foundation for Atlanta Veterans Education and Research, Inc.","startDate":"2021-09-01","conditions":"Type 2 Diabetes","enrollment":127},{"nctId":"NCT03646292","phase":"PHASE4","title":"Antidiabetic Drugs for Steatotic Liver Disease","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2018-12-06","conditions":"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes, Digestive System Disease","enrollment":51},{"nctId":"NCT04013581","phase":"PHASE4","title":"Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2019-08-05","conditions":"Type 2 Diabetes Mellitus","enrollment":121},{"nctId":"NCT02653209","phase":"PHASE4","title":"TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-11-01","conditions":"Type 2 Diabetes","enrollment":525},{"nctId":"NCT01023620","phase":"NA","title":"HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2009-10","conditions":"HIV Infections","enrollment":4},{"nctId":"NCT01055223","phase":"","title":"Fracture Risk With Thiazolidinediones","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Fractures, Bone, Type II Diabetes","enrollment":98483},{"nctId":"NCT00879970","phase":"PHASE4","title":"Thiazolidinedione Intervention With Vitamin D Evaluation","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1332},{"nctId":"NCT00683878","phase":"PHASE3","title":"Add-on to Thiazolidinedione (TZD) Failures","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Type 2 Diabetes","enrollment":972},{"nctId":"NCT00396227","phase":"PHASE3","title":"Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":2665},{"nctId":"NCT00975286","phase":"PHASE3","title":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":446},{"nctId":"NCT00402012","phase":"PHASE4","title":"\"TAKE TIME\" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM","status":"COMPLETED","sponsor":"Pennington Biomedical Research Center","startDate":"2006-11","conditions":"Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT00295633","phase":"PHASE3","title":"A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-03","conditions":"Diabetes Mellitus, Type 2","enrollment":565},{"nctId":"NCT01006018","phase":"NA","title":"DPP-4 Inhibition and TZD for DM Prevention","status":"TERMINATED","sponsor":"Emory University","startDate":"2011-07","conditions":"Prediabetic State","enrollment":3},{"nctId":"NCT01339143","phase":"PHASE4","title":"Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2010-04","conditions":"Diabetes Mellitus, Oxidative Stress","enrollment":80},{"nctId":"NCT01175486","phase":"PHASE4","title":"Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2010-07","conditions":"Diabetes","enrollment":200},{"nctId":"NCT00631007","phase":"PHASE2","title":"A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator","status":"COMPLETED","sponsor":"InteKrin Therapeutics, Inc.","startDate":"2008-02","conditions":"Type 2 Diabetes Mellitus","enrollment":367},{"nctId":"NCT00846716","phase":"NA","title":"Shiga Progression of Diabetes, Nephropathy and Retinopathy","status":"UNKNOWN","sponsor":"Shiga University","startDate":"2008-03","conditions":"Type 2 Diabetes Mellitus","enrollment":400},{"nctId":"NCT00459940","phase":"NA","title":"The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2004-09","conditions":"Growth Hormone Deficiency","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":385,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Actos"],"phase":"marketed","status":"active","brandName":"Pioglitazone - TZD","genericName":"Pioglitazone - TZD","companyName":"Royal Devon and Exeter NHS Foundation Trust","companyId":"royal-devon-and-exeter-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}